Current evidence on prevalence and clinical outcomes of co-morbid obstructive sleep apnea and chronic obstructive pulmonary disease: A systematic review.

AuthorsShawon, SR.
Hamilton, G.
Perret, J.
Senaratna, C.
Lodge, C.
Dharmage, S.C>
TypeJournal Article (Original Research)
JournalSleep Medicine Reviews
Year of Publication2016
URLhttp://www.sciencedirect.com/science/article/pii/S108707921600023X
DOIhttp://dx.doi.org/10.1016/j.smrv.2016.02.007
AbstractSummary The objective of this systematic review is to synthesize the evidence on prevalence, polysomnographic findings and clinical outcomes of co-morbid obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD) - known as the "overlap syndrome". We systematically searched PubMed on 1 December 2015 using appropriate medical subject headings (MeSH) and text words to capture prevalence studies and comparative studies of any observational design examining the clinical outcomes in patients with co-existent COPD and OSA. We reviewed 591 articles and included 27 in the final review. In total, 21 observational studies (n = 29,341 participants) provided prevalence estimates. Overlap syndrome is not common in the general and hospital population (range: 1.0 to 3.6%), but is highly prevalent in patients diagnosed with either obstructive sleep apnea (range: 7.6 to 55.7%) or COPD (range: 2.9 to 65.9%). Overlap syndrome patients have been shown to have greater nocturnal oxygen desaturation (NOD) (i.e. reduced mean peripheral capillary oxygen saturation (SpO2) and increased sleep time spent with SpO2 < 90% (T90)) and worse sleep quality than patients with only OSA. It is associated with more frequent cardiovascular morbidity, poorer quality of life (QoL), more frequent COPD exacerbation and increased medical costs. This systematic review on overlap syndrome highlights the limitations and knowledge gaps of its prevalence, etiology and underlying pathophysiologic mechanisms related to increased morbidity and mortality.

http://www.ibas.org.au/what-we-do/publications/3872820


< More publications



CHEST-MND:PROCHEST-MND:PRO

Motor neurone disease (MND) causes the body's muscles to weaken. Breathing muscle weakness means that most people affected by MND will eventually lose the ability to take a deep breath and cough strongly....

Respiratory Biomarkers in Motor Neurone DiseaseRESPIRATORY BIOMARKERS IN MOTOR NEURONE DISEASE

The inability to breathe is unfortunately the most common cause of death in people living with Motor Neurone Disease (MND). Last year, our clinical research group in Melbourne reported that breathing...

Recognising research meritRECOGNISING RESEARCH MERIT

Kudos to Dr. Lauren Booker & Dr. Jen Cori on their JOEM publication examining fatigue detection alarms in rural truck drivers. Their study explores the alarms' effectiveness, accuracy, and habituation, offering key insights into fatigue management.

Honoring Excellence in ResearchHONORING EXCELLENCE IN RESEARCH

Congratulations to Prof. Anne Holland and A/Prof. Narelle Cox for being featured in the NHMRC's 10 of the Best - 16th Edition. Their work exemplifies groundbreaking research delivering extraordinary outcomes.

World Sleep Day on 14th March 2025WORLD SLEEP DAY ON 14TH MARCH 2025

The benefits of quality sleep and to acknowledge the issue of sleep problems and their medical, educational, and social aspects as well as the prevention and management of sleep disorders, is promoted on World Sleep Day on the 14th March 2025.

AMRF Grant Awards for 2025AMRF GRANT AWARDS FOR 2025

Grants Success: The Institute for Breathing and Sleep (IBAS) has received two research grants from the Austin Medical Research Foundation (AMRF) for 2025. Congratulations to Dr Charissa Zaga and Dr Catherine Hill from IBAS.

Institute for Breathing and Sleep

Level 5, Harold Stokes Building, Austin Health
145 Studley Road
Heidelberg, Victoria, 3084

(03) 9496 5390

Email Us

Donate